Long-term renal function after donor nephrectomy

Secondary follow-up analysis of the randomized trial of ketorolac vs placebo

Gwen M. Grimsby, Paul E. Andrews, Erik P Castle, Rafael Nunez, Laurie A. Mihalik, Yu Hui H Chang, Mitchell R Humphreys

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective To evaluate the long-term safety of a novel continuous infusion of ketorolac vs placebo after laparoscopic donor nephrectomy. Methods We performed a secondary analysis of a previously reported randomized controlled trial conducted from October 7, 2008, to July 21, 2010. Patients aged 18-75 years received a continuous infusion of either ketorolac (treatment [n = 57]) or normal saline (control [n = 54]) for 24 hours immediately after laparoscopic donor nephrectomy. Serum creatinine levels were measured at 1- and 1.5-year follow-ups. Glomerular filtration rate was calculated preoperatively, postoperatively, and at 1- and 1.5-year follow-ups using the Chronic Kidney Disease Epidemiology Collaboration equation. Glomerular filtration rates were compared between treatment and control groups using 2-sample t tests. Results Data analysis for the 111 donor nephrectomy patients showed that glomerular filtration rates decreased in both groups over time, but changes were not clinically significant. No difference was found in glomerular filtration rates (in mL/min/1.73 m2) between treatment and control groups at 1-year follow-up (89.29 vs 87.94 mL/min/1.73 m2; P =.58) or at 1.5-year follow-up (88.54 vs 90.25 mL/min/1.73 m2; P =.51). Conclusion The novel provision of continuous steady-state ketorolac is safe for postoperative pain control in patients after donor nephrectomy, with no change in glomerular filtration rates between treatment and control groups acutely and at up to 1.5-year follow-up.

Original languageEnglish (US)
Pages (from-to)78-81
Number of pages4
JournalUrology
Volume84
Issue number1
DOIs
StatePublished - 2014

Fingerprint

Ketorolac
Nephrectomy
Glomerular Filtration Rate
Placebos
Tissue Donors
Kidney
Control Groups
Therapeutics
Postoperative Pain
Chronic Renal Insufficiency
Creatinine
Epidemiology
Randomized Controlled Trials
Safety
Serum

ASJC Scopus subject areas

  • Urology

Cite this

Long-term renal function after donor nephrectomy : Secondary follow-up analysis of the randomized trial of ketorolac vs placebo. / Grimsby, Gwen M.; Andrews, Paul E.; Castle, Erik P; Nunez, Rafael; Mihalik, Laurie A.; Chang, Yu Hui H; Humphreys, Mitchell R.

In: Urology, Vol. 84, No. 1, 2014, p. 78-81.

Research output: Contribution to journalArticle

Grimsby, Gwen M. ; Andrews, Paul E. ; Castle, Erik P ; Nunez, Rafael ; Mihalik, Laurie A. ; Chang, Yu Hui H ; Humphreys, Mitchell R. / Long-term renal function after donor nephrectomy : Secondary follow-up analysis of the randomized trial of ketorolac vs placebo. In: Urology. 2014 ; Vol. 84, No. 1. pp. 78-81.
@article{f075ecdab7ff4dcbb925c440d62948c3,
title = "Long-term renal function after donor nephrectomy: Secondary follow-up analysis of the randomized trial of ketorolac vs placebo",
abstract = "Objective To evaluate the long-term safety of a novel continuous infusion of ketorolac vs placebo after laparoscopic donor nephrectomy. Methods We performed a secondary analysis of a previously reported randomized controlled trial conducted from October 7, 2008, to July 21, 2010. Patients aged 18-75 years received a continuous infusion of either ketorolac (treatment [n = 57]) or normal saline (control [n = 54]) for 24 hours immediately after laparoscopic donor nephrectomy. Serum creatinine levels were measured at 1- and 1.5-year follow-ups. Glomerular filtration rate was calculated preoperatively, postoperatively, and at 1- and 1.5-year follow-ups using the Chronic Kidney Disease Epidemiology Collaboration equation. Glomerular filtration rates were compared between treatment and control groups using 2-sample t tests. Results Data analysis for the 111 donor nephrectomy patients showed that glomerular filtration rates decreased in both groups over time, but changes were not clinically significant. No difference was found in glomerular filtration rates (in mL/min/1.73 m2) between treatment and control groups at 1-year follow-up (89.29 vs 87.94 mL/min/1.73 m2; P =.58) or at 1.5-year follow-up (88.54 vs 90.25 mL/min/1.73 m2; P =.51). Conclusion The novel provision of continuous steady-state ketorolac is safe for postoperative pain control in patients after donor nephrectomy, with no change in glomerular filtration rates between treatment and control groups acutely and at up to 1.5-year follow-up.",
author = "Grimsby, {Gwen M.} and Andrews, {Paul E.} and Castle, {Erik P} and Rafael Nunez and Mihalik, {Laurie A.} and Chang, {Yu Hui H} and Humphreys, {Mitchell R}",
year = "2014",
doi = "10.1016/j.urology.2014.04.009",
language = "English (US)",
volume = "84",
pages = "78--81",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Long-term renal function after donor nephrectomy

T2 - Secondary follow-up analysis of the randomized trial of ketorolac vs placebo

AU - Grimsby, Gwen M.

AU - Andrews, Paul E.

AU - Castle, Erik P

AU - Nunez, Rafael

AU - Mihalik, Laurie A.

AU - Chang, Yu Hui H

AU - Humphreys, Mitchell R

PY - 2014

Y1 - 2014

N2 - Objective To evaluate the long-term safety of a novel continuous infusion of ketorolac vs placebo after laparoscopic donor nephrectomy. Methods We performed a secondary analysis of a previously reported randomized controlled trial conducted from October 7, 2008, to July 21, 2010. Patients aged 18-75 years received a continuous infusion of either ketorolac (treatment [n = 57]) or normal saline (control [n = 54]) for 24 hours immediately after laparoscopic donor nephrectomy. Serum creatinine levels were measured at 1- and 1.5-year follow-ups. Glomerular filtration rate was calculated preoperatively, postoperatively, and at 1- and 1.5-year follow-ups using the Chronic Kidney Disease Epidemiology Collaboration equation. Glomerular filtration rates were compared between treatment and control groups using 2-sample t tests. Results Data analysis for the 111 donor nephrectomy patients showed that glomerular filtration rates decreased in both groups over time, but changes were not clinically significant. No difference was found in glomerular filtration rates (in mL/min/1.73 m2) between treatment and control groups at 1-year follow-up (89.29 vs 87.94 mL/min/1.73 m2; P =.58) or at 1.5-year follow-up (88.54 vs 90.25 mL/min/1.73 m2; P =.51). Conclusion The novel provision of continuous steady-state ketorolac is safe for postoperative pain control in patients after donor nephrectomy, with no change in glomerular filtration rates between treatment and control groups acutely and at up to 1.5-year follow-up.

AB - Objective To evaluate the long-term safety of a novel continuous infusion of ketorolac vs placebo after laparoscopic donor nephrectomy. Methods We performed a secondary analysis of a previously reported randomized controlled trial conducted from October 7, 2008, to July 21, 2010. Patients aged 18-75 years received a continuous infusion of either ketorolac (treatment [n = 57]) or normal saline (control [n = 54]) for 24 hours immediately after laparoscopic donor nephrectomy. Serum creatinine levels were measured at 1- and 1.5-year follow-ups. Glomerular filtration rate was calculated preoperatively, postoperatively, and at 1- and 1.5-year follow-ups using the Chronic Kidney Disease Epidemiology Collaboration equation. Glomerular filtration rates were compared between treatment and control groups using 2-sample t tests. Results Data analysis for the 111 donor nephrectomy patients showed that glomerular filtration rates decreased in both groups over time, but changes were not clinically significant. No difference was found in glomerular filtration rates (in mL/min/1.73 m2) between treatment and control groups at 1-year follow-up (89.29 vs 87.94 mL/min/1.73 m2; P =.58) or at 1.5-year follow-up (88.54 vs 90.25 mL/min/1.73 m2; P =.51). Conclusion The novel provision of continuous steady-state ketorolac is safe for postoperative pain control in patients after donor nephrectomy, with no change in glomerular filtration rates between treatment and control groups acutely and at up to 1.5-year follow-up.

UR - http://www.scopus.com/inward/record.url?scp=84903639532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903639532&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2014.04.009

DO - 10.1016/j.urology.2014.04.009

M3 - Article

VL - 84

SP - 78

EP - 81

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -